Pancreatic Cancer Science—2021 in Review
As the year winds down Let’s Win provides an overall look at the highlights of 2021 in pancreatic cancer science.
Taking Life with Pancreatic Cancer One Day at a Time
François has been taking chemotherapy for his pancreatic cancer treatment and living one day at a time, to make the most of his life.
Testing a PARP Inhibitor for Metastatic Pancreatic Cancer Patients with DNA Repair Mutations
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
Chemotherapy Plus Stem Cell Infusion and Vitamins for BRCA Mutated Pancreatic Cancer
A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.
The Value of Molecular Profiling and Genetic Testing
Gina Harrison underwent molecular profiling of her pancreatic tumor, which led her to a clinical trial. Genetic testing showed her BRCA1 mutation was random and not inherited by her children.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Genetic Testing for All Pancreatic Cancer Patients
A study by Dr. Gloria Petersen’s research team has led to an official recommendation that all pancreatic cancer patients get genetic testing.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.